Guest content from John Avellanet, managing director and principal of Cerulean Associates: Follow-on biologics are a foregone conclusion in the US. Too much money is at stake. The more difficult discussion starts with how to prepare your company to compete. Science Succumbs to Dollars The financial pull on reimbursement organizations and the constituent push on […]
Browsing around the Biotechnology Industry Organization site late last night, I was surprised to find that BIO’s press release section had been hacked. No evidence of tampering elsewhere on the site, but all the news releases have been tagged by the hackers.
I’ll be at Rutgers on February 29th, giving a talk on biotechnology entrepreneurship. My objective is to dispel the popular notions about how biotechnology entrepreneurship occurs, and to provide case studies demonstrating the diversity of methods by which biotechnology entrepreneurs start and build their businesses. I’ll also provide some case studies of significant mis-steps, with […]
The following appeal for generic biologic legislation was sent in from Insmed via youtube. I’ve posted previously on the challenges of developing a framework for generic biologic approvals and questioned how much we can really expect to save. In the editorial for the upcoming issue of the Journal of Commercial Biotechnology, I argue that the […]
Courtesy of DrugPatentWatch.com: Drug Patent Expirations in February 2008*Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration CAMPTOSAR Pfizer Inc irinotecan hydrochloride 4,604,463 FEB 20,2008 CIPRO HC Alcon ciprofloxacin hydrochloride; hydrocortisone 4,844,902 FEB 11,2008 CIPRODEX Alcon ciprofloxacin; dexamethasone 4,844,902 FEB 11,2008 DEPOCYT Pacira Pharms Inc cytarabine 6,071,534 FEB 18,2008 […]